Naloxone inhibits nicotine-induced receptor current and catecholamine secretion in bovine chromaffin cells

Angelo R. Tomé, Victor Izaguirre, Luís M. Rosário, Valentín Ceña, Carmen González-García

*Department of Biochemistry, Faculty of Sciences and Technology and Center for Neuroscience and Cell Biology, University of Coimbra, Coimbra, Portugal

Centro Regional de Investigaciones Biomédicas and Departamento de Ciencias Médicas, Facultad de Medicina, Universidad de Castilla-La Mancha, Edif Benjamín Palencia, Avda. España, s/n, E-02071 Albacete, Spain

Accepted 6 March 2001

Abstract

Nicotine-induced catecholamine (CA) secretion and inward ionic currents were inhibited by the opioid antagonist naloxone in cultured bovine chromaffin cells. Naloxone inhibited nicotine-induced CA secretion, as detected by an on-line real-time electrochemical technique, in a dose-dependent manner (IC50=29 μM). In voltage-clamped chromaffin cells, nicotine (10 μM) evoked an average peak inward current of 146 pA that was inhibited by low concentrations of naloxone (42% at 0.1 μM). The antagonist also inhibited total charge influx associated with nicotinic receptor activation (53% at 0.1 μM). This provides strong evidence that naloxone modulation of nicotine-induced CA secretion does not involve opioid receptors but results from the direct interaction with the nicotinic receptor itself, which might also be the case for other related opioid compounds.

© 2001 Elsevier Science B.V. All rights reserved.

1. Introduction

Chromaffin cells secrete catecholamines (CA) in response to different stimuli [17,21]. Under physiological conditions, acetylcholine is released from splanchnic nerve terminals and interacts with nicotinic receptors producing depolarization of chromaffin cell membrane [18,23]. This depolarization opens voltage-dependent Ca2+ channels [7,11], which produces an increase in intracellular Ca2+ levels ([Ca2+]i) [2,7] and CA and ATP secretion [3,9].

Bovine chromaffin cells co-release opioid peptides together with CA following nicotinic receptor stimulation [19] and their membranes possess μ, δ and κ opioid receptors [16]. The secreted opioid peptides might inhibit nicotine-induced CA secretion from chromaffin cells [15], but this effect does not seem to be mediated by opioid receptors since opioid antagonists, like naloxone, have the same effect [8]. Moreover, it has been shown that activation of opioid κ receptors inhibits nicotine-induced Ca2+ entry into chromaffin cells but this effect is not prevented by opioid antagonists like Mr2266 [1].

Cholineric nicotinic receptors are targets for an increasing number of drugs and toxins like dihydropyridines [20], α-agatoxin IVA, a specific blocker of P/Q type voltage-dependent Ca2+ channels [13], the diuretic cyclothiazide [22] and tricyclic antidepressants [14]. Interaction of these substances with the receptor might interfere with its function.

To elucidate the mechanism of action of the inhibition of nicotine-induced CA secretion by opioid antagonists, we have studied the effect of naloxone, a well known opioid antagonist, on nicotine-induced CA secretion from chromaffin cells in a continuously superfused cellular system and explored the effect of naloxone on nicotine-
induced inward currents. We have found that the antagonist is able to inhibit, in a dose-dependent and reversible manner, nicotine-induced CA secretion and inward currents.

2. Materials and methods

2.1. Cell isolation and culture

Bovine chromaffin cells were isolated using collagenase digestion and purified through a Percoll gradient as previously described [4]. For electrophysiological recordings 10⁶ cells were plated in a 35-mm diameter Petri dish (Bibby Science Products, Stone, UK). Cultured cells were kept at 37°C under an atmosphere of 5% CO₂ for up to 5 days.

2.2. Catecholamine secretion

Catecholamine secretion experiments were performed as previously described [20] with minor modifications. Briefly, after 2–4 days of culture, chromaffin cells (ca. 2×10⁶ cells) were transferred to a perfusion chamber (a 2.3-mm diameter, 0.8-μm membrane pore, disposable filter unit) and continuously perfused at 2 ml/min with Krebs–Hepes (K-H) solution with the following composition (in mmol/l): NaCl, 140; KCl, 5; CaCl₂, 2; MgCl₂, 1; Hepes, 10; and glucose, 5; pH was adjusted to a value between 7.3 and 7.4. The cell bed was stimulated with nicotine (10 μM) every 10 min, beginning after 15 min from the start of perfusion. The effluent solution exiting the perfusion chamber was driven into an electrochemical detector (Omni 90 potentiostat, Cypress Systems, Lawrence, KS, USA) for direct continuous on-line measurement of catecholamine oxidation current (anodic potential set at +650 mV). When used, naloxone-containing solutions were perfused 2 min prior to and during nicotine application. The inhibitory effect of naloxone was calculated by comparing the area under the curve for the electrochemical signal observed in the presence of the drug with the mean area of the nicotine-induced signals observed before and after it. All the experiments were performed at room temperature (22–24°C).

2.3. Electrophysiological recording

Recording of chromaffin cell nicotinic receptor-activated currents under voltage-clamp was performed, using the nystatin-perforated patch-clamp technique, as previously described [13]. Chromaffin cells were bathed in a solution with the following ionic composition (in mmol/l): NaCl 140; KCl 5.9; MgSO₄ 1.2; CaCl₂ 2.5; Hepes 15 and glucose 11 (pH 7.4). The intracellular solution had the following composition (in mmol/l): KCl 55; K₂SO₄ 50; MgSO₄ 7; Hepes 10 and nystatin 250 μg/ml (pH 7.2). After 10 min, nicotine (10 μM) was applied for 4 s using a fast perfusion system under computer control (DAD-12 superfusion system; Adams and List, NY). This nicotine pulse was repeated three times (S₁, S₂, S₃) at 15-min intervals. When used, naloxone was perfused 1 s before and during S₂.

2.4. Reagents

Nicotine and naloxone were obtained from Sigma (St Louis, MO) penicillin and streptomycin from Bio-Whittaker Bioproducts (Walkersville, MD) and bovine serum albumin from Calbiochem (La Jolla, CA). All other reagents were obtained from different commercial sources and were of the maximal available purity.

3. Results

3.1. Catecholamine secretion

Introduction of nicotine (10 μM) in the perfusion flow resulted in the detection of a transitory CA secretion indicating that the agonist induced CA release from the chromaffin cells present in the perfusion chamber [5]. The electrochemical signal was equivalent to the release of 1.0±0.3 nmol CA/10⁶ cells (mean±S.E.M., n=3). The amplitude of the electrochemical signal tended to decrease as the stimulation of CA secretion with nicotine was repeated every 10 min (Fig. 1A). Naloxone produced a marked decrease in the nicotine-induced secretory episodes. The inhibitory effect of naloxone on the nicotine-induced CA release was dose-dependent. The blockade was almost complete at the highest drug concentration used, 200 μM (96±2% inhibition, n=5; Fig. 1, panel A). The IC₅₀ for the blocking effect of naloxone, as determined from the dose–response curve, was 29 μM (Fig. 1B).

3.2. Nicotine-induced inward currents

Nicotine (10 μM) perfusion for 4 s evoked an inward current that amounted to −146±27 pA (n=19), producing a total net charge flux of 495±56 pC (n=19). When the exposure to nicotine was repeated 15 min later, the ratio S₂/S₁ for peak current was 0.94±0.07 (n=5) and for charge influx was 1.02±0.09 (n=5). The presence of naloxone during S₂ produced a marked decrease in both peak current and charge influx that was reversible upon removal of the drug (Fig. 2). The inhibitory effect of naloxone was dose-dependent. The blockade reached around 65% for peak current and 68% for total charge influx at 10 μM drug concentration (Table 1).
Fig. 2. Nicotine-induced inward currents in chromaffin cells. Inward currents evoked by three successive exposures (S1, S2, S3; 4 s; 15 min apart) to nicotine (10 μM) from a holding potential of −55 mV. Naloxone (10 μM) was present 1 s before and during S1. The experiment was repeated six more times with similar results.

likelyhood, has removed the locally secreted products. The inhibitory mechanism of opioids on nicotine-evoked CA secretion has been controversial since the lack of stereospecificity [8] and non reversion by opioid antagonists [1,8] were shown suggesting that specific opioid receptors were not involved in this action. Our electrophysiological data support this proposal and indicate that the nicotinic receptor might be a target through which opioid drugs might regulate directly nicotinic receptor-mediated functions. Noteworthy is the fact that the cholinergic nicotinic receptors from chromaffin cells have been shown to interact with a broad range of unrelated compounds [6,12,13,22] indicating that such a process might be a pharmacologically relevant mechanism to regulate chromaffin cell secretory activity.

In summary, the data presented here suggest that the non-selective opioid antagonist naloxone potently blocks nicotine-induced CA secretion from chromaffin cells and this effect might be explained by the reversible blockade of nicotine-induced inward currents in chromaffin cells.

Chromaffin cells in culture might secrete and accumulate in its vicinity different products, including endogenous opioids [19], that might produce a negative feedback on secretion. Support for this view comes from studies that indicate cell superfusion resulting in fast removal of locally secreted products produces an increase in Ca2+ current amplitude [10]. Our data indicate that this mechanism is not involved in naloxone effects because, in order to prevent tonic modifications of nicotinic receptor-mediated functions, both the CA secretion studies and electrophysiological recordings have been performed under continuous fast superfusion of chromaffin cells that, in all

4. Discussion

The results presented here show that the non-selective opioid antagonist naloxone potently blocks nicotine-induced CA secretion from chromaffin cells and this effect might be explained by the reversible blockade of nicotine-induced inward currents in chromaffin cells.

Chromaffin cells in culture might secrete and accumulate in its vicinity different products, including endogenous opioids [19], that might produce a negative feedback on secretion. Support for this view comes from studies that indicate cell superfusion resulting in fast removal of locally secreted products produces an increase in Ca2+ current amplitude [10]. Our data indicate that this mechanism is not involved in naloxone effects because, in order to prevent tonic modifications of nicotinic receptor-mediated functions, both the CA secretion studies and electrophysiological recordings have been performed under continuous fast superfusion of chromaffin cells that, in all

Table 1

<table>
<thead>
<tr>
<th>Drug added together with nicotine during S1</th>
<th>n</th>
<th>Peak current (S1/S0 ratio)</th>
<th>Total net charge influx (S1/S0 ratio)</th>
</tr>
</thead>
<tbody>
<tr>
<td>None</td>
<td>5</td>
<td>0.94±0.07</td>
<td>1.02±0.09</td>
</tr>
<tr>
<td>Naloxone 0.1 μM</td>
<td>7</td>
<td>0.54±0.05*</td>
<td>0.47±0.06*</td>
</tr>
<tr>
<td>Naloxone 10 μM</td>
<td>7</td>
<td>0.33±0.03**</td>
<td>0.33±0.03**</td>
</tr>
</tbody>
</table>

Bovine chromaffin cells were exposed for 4 s to nicotine (10 μM) as stated in Material and methods. Nicotine stimulation was repeated three times (S1, S2, S3) at 15-min intervals. Naloxone was perfused to the cell 1 s before and during S1. The average values for inward peak current and total net charge influx during S1 were −146±27 pA (n=19) and 495±56 pC (n=19). Data represent mean±S.E.M. 

*P<0.001; **P<0.0001 compared to control.
and that opioid-mediated inhibition of nicotine-evoked CA secretion is not mediated by specific opioid receptors.

Acknowledgements

This work has been supported in part by grants SAF96-0169 and 1FD97-0500 from CICYT to V.C.; PRAXIS 2/2.1/SAU/1179/95 from Fundação para a Ciência e Tecnologia (FCT) to L.M.R. and SAF98-0140 from CICYT to C.G.G.

References